



## Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5) today announced that the Company will participate in the 44<sup>th</sup> Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day.

A webcast of the presentation will be available [here](#) beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be posted on the Investors section of the Company's [website](#).

### About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRY5) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK<sup>®</sup>, the Company's first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [X](#) (formerly Twitter).

### CONTACT

#### Investors and Media:

Stéphane Paquette

Krystal Biotech

[spaquette@krystalbio.com](mailto:spaquette@krystalbio.com)



Source: Krystal Biotech, Inc.